Abstract
Background & aims Genome-wide association studies in adults have identified variants in HSD17B13 and MARC1 as protective against NAFLD. It is not known if they are similarly protective in children and, more generally, whether the peri-portal inflammation of pediatric NAFLD and lobular inflammation seen in adults share common genetic influences. Therefore, we aimed to: establish if these variants are associated with NAFLD in children, and to investigate the function of these variants in hepatic metabolism using metabolomics.
Methods 960 children (590 with NAFLD, 394 with liver histology) were genotyped for rs72613567T>TA in HSD17B13, rs2642438G>A in MARC1. Genotype-histology associations were tested using ordinal regression. Untargeted hepatic proteomics and plasma lipidomics were performed in a subset of samples. In silico tools were used to model the effect of rs2642438G>A (p.Ala165Thr) on MARC1.
Results rs72613567T>TA in HSD17B13 was associated with lower odds of NAFLD diagnosis (OR 0.7 (95%CI 0.6-0.9) and lower grade of portal inflammation (P<0.001) whilst rs2642438G>A in MARC1 was associated with lower grade of hepatic steatosis (P=0.02). Proteomics found reduced expression of HSD17B13 in carriers of the protective allele, whereas MARC1 levels were not affected by genotype. Both variants showed downregulation of hepatic fibrotic pathways, upregulation of retinol metabolism and perturbation of phospholipid species. Modelling suggests that p.Ala165Thr would disrupt the stability and metal-binding of MARC1.
Conclusions There are shared genetic mechanisms between pediatric and adult NAFLD, despite their differences in histology. MARC1 and HSD17B13 are involved in phospholipid metabolism and suppress fibrosis in NAFLD.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Clintrials.gov NCT04190849
Funding Statement
CAH, DM and SW are supported by the German Systems Biology Program (LiSyM - grant no. 31L0057 and 31L0058) sponsored by the German Federal Ministry of Education and Research (BMBF). JPM is supported by a Wellcome Trust fellowship (216329/Z/19/Z), a European Society for Paediatric Research (ESPR) Young Investigator Award, and a Childrens Liver Disease Foundation Grant. EU-PNAFLD Registry is supported by an European Association for Study of the Liver (EASL) Registry Grant and by the Newcastle NIHR Biomedical Research Centre/Newcastle University using a database infrastructure developed by the EU EPoS consortium. AA is supported by grant from Italian Ministry of Health (5x1000). SF was supported by funding form BBSRC (BB/M027252/1, original proposal written by AK). BK is supported by grants from Van den Broek Lohman Foundation, Virtutis Opus Foundation and For Wishdom Foundation. QMA in a Newcastle NIHR Biomedical Research Centre investigator and a member of the EU H2020 EPoS (Elucidating Pathways of Steatohepatitis) and EU IMI2 LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortia funded under grant agreements 634413 and 777377 respectively.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
East Midlands - Nottingham 2 Research Ethics Committee (17/EM/0084) Maastricht University Medical Centre (under ethical approval METC 13-4-130) Amsterdam University Medical Centre (under ethical approval MEC 2017_306 and MEC 07/141) Bambino Gesu hospital (protocol number 1774_OPBG_2019) Charite Berlin (under ethical approval of the local institutional review board EA2/049/14).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Full summary statistics available in Data Supplement.
